Associations between serum albumin and serious non-AIDS events among people living with HIV

Andreas RONIT, Camilla Ingrid HATLEBERG, Lene RYOM, Fabrice BONNET, Wafaa EL-SADR, Peter REISS, Rainer WEBER, Christian PRADIER, Stephane De WIT, Matthew LAW, Antonella d’Arminio MONFORTE, Jens LUN DGREN, Amanda MOCROFT, Andrew N PHILLIPS, Caroline A SABIN, for the D:A:D Study group

Running title: Serum albumin and non-AIDS events
Corresponding author:

Andreas Ronit, MD

Department of Infectious Diseases 8632,

University Hospital Rigshospitalet, Blegdamsvej 9; DK-2100 Copenhagen Ø; Denmark

E-Mail: andreas.ronit@regionh.dk; Phone: (+45) 3545 0859, Fax: (+45) 3545 6648
Abstract

Objective: Lower serum albumin (sAlb) has been associated with an increased risk of mortality and AIDS among people living with HIV and may be associated with the development of serious non-AIDS events (SNAEs). We evaluated the long-term association between sAlb and the risk of SNAEs.

Design: Prospective multinational cohort study.

Methods: D:A:D participants without SNAEs were followed from first routine sAlb value to the first of a new SNAE [cardiovascular disease (CVD), end-stage liver disease (ESLD), end-stage renal disease (ESRD), non-AIDS malignancy (NADM), death from non-AIDS cause], AIDS-death, 6 months after last visit or 01/02/2016. Poisson regression was used to determine associations between sAlb and a new i) SNAE, ii) CVD or iii) NADM event, with adjustment for potential confounders. Models additionally tested whether the associations were modified by age, follow-up time, smoking status, CD4 and viral load.

Results: Of 16,350 participants (71.8% male, median age 44 years) 1,463 developed a SNAE (371 CVD, 200 ESLD, 40 ESRD, 553 NADM, 299 deaths from other non-AIDS causes) over 80,264 person-years. Increased sAlb was associated with a decreased risk of an SNAE (adjusted rate ratio (aRR) per 5g/L: SNAE 0.79 [95%CI: 0.76, 0.83]; CVD 0.87 [0.80, 0.94]; NADM 0.88 [0.82, 0.95]). The association did not appear to wane with additional years of follow-up (p-interaction=0.79) but was stronger for current smokers than for never smokers (p-interaction<0.01).

Conclusions: sAlb is a durable risk factor for SNAE. Future studies are needed to determine the mechanism underlying this association and to evaluate the value of sAlb in predictive tools.

Keywords: albumin, biomarker, cancer, CVD, non-AIDS comorbidity, smoking
INTRODUCTION

Exploring novel associations between biomarkers and serious non-AIDS events (SNAE) may inform disease pathogenesis. Low serum albumin (sAlb) has consistently been associated with AIDS progression and all-cause mortality in people living with HIV (PLWH) [1-6]. Moreover, the association of sAlb with SNAE was recently assessed in the INSIGHT START Study [7]. SAlb was independently associated with SNAE over the short-term and, potentially, over the longer term. Due to a limited sample size and duration of follow-up, this study was not powered to detect associations with specific SNAE, assess important effect modifiers, or to determine the duration over which the association remained present.

Using data from the Data on Adverse Events of Antiretroviral Drugs (D:A:D) Study we aimed to undertake a detailed evaluation of the association between sAlb and SNAE in a larger and more heterogeneous study population with longer follow-up.

METHODS

Study design

The D:A:D Study is an observational study following approximately 50,000 PLWH from 11 cohorts in Europe, USA and Australia. Collected data include information on socio-demographic factors, HIV-related factors including AIDS events and antiretroviral treatment (ART) regimens, and other non-AIDS risk factors.

A SNAE was systematically collected (https://www.chip.dk/Studies/DAD/Study-Documents) and defined as CVD (myocardial infarction, stroke, invasive cardiovascular procedure or death from CVD); end-stage renal disease (ESRD) or death from renal disease; end-stage liver disease
(ESLD) or death from ESLD; non-AIDS-defining malignancies (NADMs, except for basal cell or squamous cell skin cancer) or death from cancer; and any other non-AIDS death.

We excluded cohorts that did not provide any or sparse sAlb data (online supplement M1, http://links.lww.com/QAD/B297). We selected a baseline date for each cohort which reflected the time at which the coverage of sAlb measurements increased to a level that suggested routine monitoring. As the systematic collection of some SNAE did not commence until 1st February 2004, each cohort-specific baseline date was set to the later of this date or the date of routine sAlb monitoring. The date of the closest sAlb measurement to this cohort-specific date (as long as the sAlb had been measured less than one year prior to this date) was taken to be the individual baseline date. Individuals without a sAlb measurement in this window were excluded, as were those who already had a SNAE at their baseline.

**Statistical methods**

Study participants were followed from baseline to the date of each endpoint; follow-up for each person was censored on the date of an AIDS death, six months after the last clinic visit or on 1st February 2016, whichever occurred earliest. Follow-up times for analyses of the CVD and NADM endpoints were additionally censored on the date of a non-CVD/non-NADM SNAE.

Poisson regression was used to model the rate of the three endpoints; unadjusted and adjusted rate ratios (RR/aRR) and 95% confidence intervals (CIs) were computed. We considered a fixed model with covariates defined on the baseline date.

Selection of confounders for inclusion in multivariable models was based on available information about the relation between sAlb and SNAE. Covariates that were included were participating cohort, gender, risk group, race, age, body-mass index (BMI), smoking status
(current smoker, ex-smoker, never smoker, unknown), dyslipidaemia (total cholesterol (TC) ≥6.2 mmol/l, high-density lipoprotein cholesterol (HDL-C) ≤0.9 mmol/l, TC:HDL-C ratio ≥6.5 or receipt of lipid lowering drug), ALT and estimated glomerular filtration rate (eGFR)(Cockcroft-Gault equation), hepatitis C-virus (HCV)(positivity by anti-HCV and/or HCV RNA positive), hepatitis B-virus (HBV)(positivity by HBsAg, HBeAg or HBV-DNA positive/anti-HBe positive), CD4 count, viral load (VL)<50 copies/ml, current exposure to each antiretroviral class. All variables were continuous unless specified otherwise.

We also assessed interactions between i) sAlb and age; ii) sAlb and cigarette smoking; iii) sAlb and follow-up time; iv) sAlb and baseline CD4 count; and v) sAlb and the latest HIV RNA (as a time-updated covariate). Analyses were conducted in SAS version 9.3.

RESULTS

Of the 33,750 potentially eligible individuals, 16,350 had a baseline sAlb measurement and were free of SNAE at this time. The characteristics of the individuals excluded at this stage did not differ substantially from those of the included participants (male 74.1% vs. 71.8%; heterosexual 35.5% vs. 36.4%; white ethnicity 50.0% vs. 50.5%; median age 38 vs. 37 years; previous exposure to ART 62.4% vs. 63.3%, median CD4 cell count 408 vs. 420 cells/mm³). A detailed description of study participants is provided in online supplement M2, http://links.lww.com/QAD/B297.

Study participants were followed for a total of 80,264 person-years (PYRS), during which 1463 SNAE were observed. This included 371 (25.4%) CVD events, 553 (37.8%) NADM events, 200 (13.7%) ESLD events, 40 (2.7%) ESRD events and 299 (20.4%) deaths from other SNAE.
PYRS, event rates, and number of events stratified by sAlb levels are depicted in online supplement M3, http://links.lww.com/QAD/B297.

Lower sAlb was associated with all events considered and RRs were only modified slightly after adjustment (Table 1). Moreover, various strata of lower levels of sAlb appeared to be associated with higher SNAE rates suggesting a linear association. Whilst associations were numerically weaker for the CVD and NADM endpoints, the trend for a higher event rate in those with lower sAlb levels was still apparent (online supplementary M2, http://links.lww.com/QAD/B297).

We tested several interactions (Figure 1). The association between sAlb and SNAE was slightly stronger in younger individuals (p-interaction<0.001). For SNAE the association with sAlb seemed to differ by baseline CD4+ cell count with the strongest effect seen among individuals with CD4+ cell counts below 200 cells/mm$^3$ (p-interaction<0.001). The association between sAlb and SNAE was still evident six years after baseline sAlb measurement in the fully adjusted model and there was no evidence that the association between sAlb and SNAE changed over time (p-interaction=0.79). We found evidence for an interaction between smoking and sAlb with a stronger association for current smokers compared to never smokers (aRR 0.76 [95%CI: 0.73-0.80] vs aRR 0.87 [95%CI: 0.80-0.95], p<0.01). Finally, analyses revealed some effect modification with the latest viral load for the SNAE, with associations being slightly stronger in those with a non-suppressed viral load (p-interaction<0.001).

**DISCUSSION**

We found a strong association between lower sAlb and SNAE. This observation was consistent across different SNAE and did not appear to wane over time since sAlb measurement. The
association between sAlb and SNAE appeared to be stronger in younger individuals and in current smokers.

Several studies have found an association between sAlb and all-cause mortality in PLWH. One of the earliest studies from the Women’s Interagency HIV Study suggested that sAlb could be associated with non-AIDS causes of mortality, as sAlb was found to be a more strongly associated with mortality in individuals with high CD4 counts [3]. A US veterans study confirmed this and noted a strong independent association between sAlb and atherosclerotic CVD events and heart failure [5]. SAlb was also recently shown to be associated with SNAE in the START study. Our study confirmed these findings and demonstrated that sAlb was associated with both CVD and NADM.

Several factors may confound our observations. Although low sAlb is commonly regarded as a marker of nutritional status, it is poorly associated with other measures of nutritional status in the general population and in PLWH [8, 9]. Other causes of low sAlb may include liver disease (decreased synthesis), enhanced turnover resulting from either increased catabolism or enhanced loss of albumin into the urine or intestine [10], or trans-capillary loss due to increased vascular permeability [11]. The acute phase response, of which interleukin (IL)-6 is a potent inducer, to infectious conditions, neoplastic growth, or immunological disorders, is also associated with inhibition of liver protein synthesis in animal studies [12]. A lowering of sAlb may therefore reflect the chronic inflammation that has been associated with HIV infection [13]. In the START study, however, sAlb was associated with SNAE even after adjusting for IL-6 levels [7]. A low sAlb level might be a consequence of other pathways of immune activation that may be less directly associated with the inflammatory marker IL-6. Moreover, the neonatal Fc receptor, expressed in many different cell types and induced by pro-inflammatory cytokines like TNF-α
and IL-1β [14], protects sAlb from degradation [15]. Finally, sAlb may exert a protective effect due to antioxidant activity, binding capacity of endogenous and exogenous compounds (e.g. fatty acids and carcinogens) [16], or its anti-thrombotic effects [17].

We also showed that sAlb was associated with disease endpoints even when the level was measured six years before the occurrence of a SNAE and when sAlb was within the range of levels commonly considered as normal (>35 g/L). Individuals with sAlb levels of 35-40 g/L (low-normal), controlling for other factors, were more likely to experience a SNAE than individuals with levels of 40-45 g/L (high-normal). SAlb even seemed to exert a protective effect at high levels (>45 g/L). Thus, the association with SNAE appeared to be linear with no obvious threshold effect.

A few interventions may cause changes to sAlb levels. Initiation of cART was associated with higher sAlb concentration during follow-up when compared to participants who deferred cART initiation [7]. Smoking cessation has been associated with increases in sAlb with levels changing towards those of never smokers within five years [18]. We showed that the association between sAlb and SNAE was strongest in current smokers, in line with earlier studies from the general population [18, 19]. Mechanisms underlying the potential effects of interventions on sAlb levels or in which ways factors modify the association between sAlb and SNAE are unknown. As the correlation between cumulative smoking and sAlb was weak, it was previously suggested that those smokers with lowest sAlb levels were those with the greatest inflammatory response to smoking [18]. Consistent with this, newer evidence shows that smoking is associated with extensive alterations in systemic markers of inflammation of which many revert back to levels of never smokers after smoking cessation [20]. sAlb levels may consequently be a proxy for susceptibility to the effect of noxious stimuli, such as smoking, but potentially also to
inflammation associated with HIV. Accordingly, we also observed an association between sAlb and SNAE in those who reported never smoking in contrast to studies from the general population [18, 19], and we showed that viral suppression modified the association between sAlb and SNAE, which indicate that the association is not driven completely independent of HIV.

Our study has limitations. First, SAlb concentrations were measured irregularly in the contributing cohorts. To avoid the confounding effect of increased monitoring in sick individuals, we considered a fixed timepoint analysis. Secondly, not all eligible individuals had a sAlb measurement, which may have introduced selection bias, although we observed characteristics of individuals with and without sAlb measurements to be similar.

In conclusion, sAlb was found to be independently associated with SNAE, including CVD and NADM. This association did not appear to wane over time and was strongest in current smokers. The pathophysiology underlying the relationship between sAlb and SNAE, and its effect modifiers, are poorly understood, and warrants further mechanistic investigation.

Contributions

AR, CIH, LR, JDL, AP, and CS developed the initial analysis protocol. CIH and LR performed study coordination and prepared the datasets for analysis. CS performed the statistical analyses. AR prepared the first draft of the manuscript and completed all revisions. All authors provided critical input at all stages of the preparation of the manuscript.

Declaration of interests

AR, CIH, LR, FB, WES, RW, SdW, JDL, and ANP have no disclosures to declare. PR has through his institution received independent scientific grant support from Gilead Sciences,
Janssen Pharmaceutical Inc, Merck & Co, Bristol-Myers Squibb and ViiV HealthCare; he has served on scientific advisory board for Gilead Sciences and a data safety monitoring committee for Janssen Pharmaceuticals Inc; he chaired a scientific symposium by ViiV HealthCare, for which his institution has received remuneration. CP reports non-financial support from Janssen, personal fees from Gilead Sciences, non-financial support from ViiV HealthCare and non-financial support from MSD. ML has received unrestricted grants from Boehringer Ingelheim, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen-Cilag and ViiV HealthCare; he also received consultancy payments from Gilead Sciences, and DSMB sitting fees from Sirtex Pty Ltd. AdAM has received grants for advisory boards or lectures by Abbve, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD and ViiV HealthCare. AM has received travel support, honoraria, speaker fees and/or lecture fees from Bristol-Myers Squibb, Gilead Sciences, ViiV HealthCare, Pfizer, Merck, BI and Wragge LLC. CS has received funding for membership of Data Safety and Monitoring Boards, Advisory Boards, speaker panels and for preparation of educational materials from Gilead Sciences, ViiV HealthCare and Janssen-Cilag.

Financial support

The D:A:D study was supported by a grant [grant number DNRF126] from the Danish National Research Foundation (CHIP & PERSIMUNE); the Highly Active Antiretroviral Therapy Oversight Committee (HAARTOC), a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the United States Food and Drug Administration, the patient community, and pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc., ViiV Healthcare, Merck & Co Inc. and Janssen Pharmaceuticals. Supported also by a grant from the Dutch Ministry of Health, Welfare and Sport through the Center for
Infectious Disease Control of the National Institute for Public Health and the Environment to Stiching HIV Monitoring (ATHENA); by a grant from the Agence nationale de recherches sur le sida et les hépatites virales [ANRS, Action Coordonnée no.7, Cohortes] to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by a grant from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) [grant number U01-AI069907] and by unconditional grants from Merck Sharp & Dohme; Gilead Sciences; Bristol-Myers Squibb; Boehringer Ingelheim; Janssen-Cilag; ViiV Healthcare. The Kirby Institute is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales; by grants from the Fondo de Investigación Sanitaria [grant number FIS 99/0887] and Fundación para la Investigación y la Prevención del SIDA en Espana [grant number FIPSE 3171/00], to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health [grants number 5U01AI042170-10, 5U01AI046362-03], to the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); by primary funding provided by the European Union’s Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement n° 260694 and unrestricted grants by Bristol-Myers Squibb, Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC, (the participation of centres from Switzerland is supported by The Swiss National Science Foundation (Grant 108787)) to the EuroSIDA study; by unrestricted educational grants of AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); and financed within the framework of the
Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant #148522) and by the SHCS research foundation.

Acknowledgements D:A:D Study group

D:A:D Participating Cohorts

Aquitaine, France; CPCRA, USA; NICE Cohort, France; ATHENA, The Netherlands; EuroSIDA, Europe; SHCS, Switzerland, AHOD, Australia; HIV-BIVUS, Sweden; St.Pierre Brussels Cohort, Belgium; BASS, Spain, The ICONA Foundation, Italy

D:A:D Steering Committee: Names marked with *, Chair with €

Cohort PIs: W El-Sadr* (CPCRA), G Calvo* (BASS), F Bonnet and F Dabis* (Aquitaine), O Kirk* and A Mocroft* (EuroSIDA), M Law* (AHOD), A d’Arminio Monforte* (ICONA), L Morfeldt* (HIVBIVUS), C Pradier* (Nice), P Reiss* (ATHENA), R Weber* (SHCS), S De Wit* (Brussels)

Cohort coordinators and data managers: A Lind-Thomsen (coordinator), R Salbøl Brandt, M Hillebreght, S Zaheri, FWNM Wit (ATHENA), A Scherrer, F Schöni-Affolter, M Rickenbach (SHCS), A Tavelli, I Fanti (ICONA), O Leleux, J Mourali, F Le Marec, E Boerg (Aquitaine), E Thulin, A Sundström (HIVBIVUS), G Bartsch, G Thompsen (CPCRA), C Necsoi, M Delforge (Brussels), E Fontas, C Caissotti, K Dollet (Nice), S Mateu, F Torres (BASS), K Petoumenos, A Blance, R Huang, R Puhr (AHOD), K Grønborg Laut, D Kristensen (EuroSIDA)

Statisticians: CA Sabin*, AN Phillips*, DA Kamara, CJ Smith, A Mocroft*

D:A:D coordinating office: CI Hatleberg, L Ryom, A Lind-Thomsen, RS Brandt, D Raben, C Matthews, A Bojesen, AL Grevesen, JD Lundgren*€
Member of the D:A:D Oversight Committee: B Powderly*, N Shortman*, C Moecklinghoff*, G Reilly*, X Franquet*

D:A:D working group experts:

Kidney: L Ryom, A Mocroft*, O Kirk *, P Reiss*, C Smit, M Ross, CA Fux, P Morlat, E Fontas, DA Kamara, CJ Smith, JD Lundgren *¢


External endpoint reviewers: A Sjøl (CVD), P Meidahl (oncology), JS Iversen (nephrology)

Funding: Grant number DNRF126] from the Danish National Research Foundation (CHIP & PERSIMUNE); ‘Oversight Committee for The Evaluation of Metabolic Complications of HAART’ with representatives from academia, patient community, FDA, EMA and a consortium of AbbVie, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck and Janssen Pharmaceuticals.

The current members of the 11 Cohorts are as follows:

ATHENA (AIDS Therapy Evaluation Project Netherlands):

Central coordination: P. Reiss*, S. Zaheri, M Hillebregt, F.W.N.M. Wit;

CLINICAL CENTRES (¤ denotes site coordinating physician) Academic Medical Centre of the University of Amsterdam: J.M. Prins¤, T.W. Kuijpers, H.J. Scherbier, J.T.M. van der Meer,

**Aquitaine Cohort (France)**

Composition du Conseil scientifique :

Coordination: F. Bonnet, F. Dabis

Wittkop, L. Wittkop, O. Leleux, S. Lawson-Ayayi, A. Gimbert, S. Desjardin, L. Lacaze-Buzy, V. Petrov-Sanchez

Epidemiology and Methodology: F. Bonnet, G. Chêne, F. Dabis, R. Thiébaut, L. Wittkop


Immunology: I. Pellegrin, P. Blanco

Virology: H. Fleury, Me. Lafon, P. Trimoulet, P. Bellecave, C. Tumiotto

Pharmacology: S. Bouchet, D. Breilh, F. Haramburu, G. Miremeont-Salamé


IT department and eCIRF development: G. Palmer, V. Conte, V. Sapparrart

AHOD (Australian HIV Observational Database, Australia):

Central coordination: M. Law *, K. Petoumenos, R Puhr, R Huang (Sydney, New South Wales).

Participating physicians (city, state): R. Moore, S. Edwards, J. Hoy, K. Watson, N. Roth, H Lau
(Melbourne, Victoria); M Bloch, D. Baker, A. Carr, D. Cooper, (Sydney, New South Wales); M O’Sullivan (Gold Coast, Queensland), D. Nolan, G Guelfi (Perth, Western Australia).

**BASS (Spain):**

Central coordination: G. Calvo, F. Torres, S. Mateu (Barcelona);

Participating physicians (city): P. Domingo, M.A. Sambeat, J. Gatell, E. Del Cacho, J. Cadafalch, M. Fuster (Barcelona); C. Codina, G. Sirera, A. Vaqué (Badalona).

The Brussels St Pierre Cohort (Belgium):

Coordination: S. De Wit*, N. Clumeck, M. Delforge, C. Necsoi.


**The Brussels St Pierre Cohort (Belgium):**

Coordination: S. De Wit*, N. Clumeck, M. Delforge, C. Necsoi.


**CPCRA (USA):**

Central coordination: J. Neaton, G. Bartsch, W.M. El-Sadr*, E. Krum, G. Thompson, D. Wentworth;

Participating physicians (city, state): R. Luskin-Hawk (Chicago, Illinois); E. Telzak (Bronx, New York); W.M. El-Sadr (Harlem, New York); D.I. Abrams (San Francisco, California); D. Cohn (Denver, Colorado); N. Markowitz (Detroit, Michigan); R. Arduino (Houston, Texas); D.
Mushatt (New Orleans, Louisiana); G. Friedland (New Haven, Connecticut); G. Perez (Newark, New Jersey); E. Tedaldi (Philadelphia, Pennsylvania); E. Fisher (Richmond, Virginia); F. Gordin (Washington, DC); L.R. Crane (Detroit, Michigan); J. Sampson (Portland, Oregon); J. Baxter (Camden, New Jersey).

**EuroSIDA (multinational)**

Steering Committee: J Gatell, B Gazzard, A Horban, I Karpov, M Losso, A d’Arminio Monforte, C Pedersen, M Ristola, A Phillips, P Reiss, J Lundgren, J Rockstroh

Chair: J Rockstroh

Study Co-leads: A Mocroft, O Kirk

Coordinating Centre Staff: O Kirk, L Peters, C Matthews, AH Fischer, A Bojesen, D Raben, D Kristensen, K Grønborg Laut, JF Larsen, D Podlekareva

Statistical Staff: A Mocroft, A Phillips, A Cozzi-Lepri, L Shepherd, A Schultze, S Amele

The multi-centre study group, EuroSIDA (national coordinators in parenthesis).

Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires.

Austria: (B Schmied), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical University Innsbruck, Innsbruck.

Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM Mitsura, Gomel State Medical University, Gomel; D Paduto, Regional AIDS Centre, Svetlogorsk.
Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels; E Florence, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis Gent, Gent.

Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, Sarajevo.

Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb.

Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University Hospital, Plzen.

Denmark: G Kronborg, T Benfield, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, Rigshospitalet, Copenhagen; NF Møller, C Pedersen, Odense University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus, L Wiese, Roskilde Hospital, Roskilde; L N Nielsen, Hillerod Hospital, Hillerod.

Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond Siseklinik, Kohtla-Järve.

Finland: (M Ristola), I Aho, Helsinki University Central Hospital, Helsinki.

France: (J-P Viard), Hôtel-Dieu, Paris; P-M Girard, Hospital Saint-Antoine, Paris; C Pradier, E Fontas, Hôpital de l'Arche, Nice; C Du vivier, Hôpital Necker-Enfants Malades, Paris.

Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule Hannover; O Degen, University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; C Stefan, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln, Cologne.
Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi

Greece: (P Gargalianos), G Xylenos, K Armenis, Athens General Hospital "G Gennimatas"; H Sambatakou, Ippokration General Hospital, Athens.

Hungary: (J Szlávik), Szent László Hospital, Budapest.

Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik.

Ireland: (F Mulcahy), St. James's Hospital, Dublin.

Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; E Shahar, G Hassoun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah University Hospital, Jerusalem; D Elbirt, ZM Sthoeger, AIDS Center (Neve Or), Jerusalem.

Italy: (A D’Arminio Monforte), Istituto Di Clinica Malattie Infettive e Tropicale, Milan; R Esposito, I Mazeu, C Mussini, Università Modena, Modena; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; M Zaccarelli, A Antinori, R Aeinapura, M Plazzi, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan.

Latvia: (B Rozentale), Infectology Centre of Latvia, Riga.

Lithuania: (V Uzdaviniene) Vilnius University Hospital Santariskiu Klinikos, Vilnius; R Matulionyte, Center of Infectious Diseases, Vilnius University Hospital Santariskiu Klinikos, Vilnius.

Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, Luxembourg.
Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam.

Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo.

Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A Horban, E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak, A Grzeszczuk, Medical University, Bialystok; M Parczewski, K Maciejewska, B Aksak-Was, Medical University, Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; T Smiatacz, M Gensing, Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz; I Mozer-Lisewska, Poznan University of Medical Sciences, Poznan.

Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.

Romania: (R Radoi), C Oprea, Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, Bucarest.

Russia: (A Panteleev), O Panteleev, St Petersurg AIDS Centre, St Peterburg; A Yakovlev, Medical Academy Botkin Hospital, St Petersburg; T Trofimova, Novgorod Centre for AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious Diseases, Kaliningrad; E Kuzovatova, Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina, Nizhny Novogrod; E Borodulina, E Vdoushkina, Samara State Medical University, Samara.

Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.

Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona, Barcelona; S Moreno, J. M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, Vitoria-Gasteiz.

Sweden: (K Falconer), A Thalme, A Sonnerborg, Karolinska University Hospital, Stockholm; A Blaxhult, Venhälsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University Hospital, Malmö.

Switzerland: (A Scherrer), R Weber, University Hospital Zurich; M Cavassini, University Hospital Lausanne; A Calmy, University Hospital Geneva; H Furrer, University Hospital Bern; M Battegay, University Hospital Basel; P Schmid, Cantonal Hospital St. Gallen.

Ukraine: A Kuznetsova, Kharkov State Medical University, Kharkov; G Kyselyova, Crimean Republican AIDS centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention and Control CTR, Lviv.

United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea and Westminster Hospital, London; AM Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A Phillips, MA Johnson, A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); C Orkin, Royal London Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. Mary's, London; A Clarke, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh.

The following centers have previously contributed data to EuroSIDA:
Infectious Diseases Hospital, Sofia, Bulgaria

Hôpital de la Croix Rousse, Lyon, France

Hôpital de la Pitié-Salpétière, Paris, France

Unité INSERM, Bordeaux, France

Hôpital Edouard Herriot, Lyon, France

Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany

1st I.K.A Hospital of Athens, Athens, Greece

Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy

Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy

Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, Italy

Dérer Hospital, Bratislava, Slovakia

Hospital Carlos III, Departamento de Enfermedades Infecciosas, Madrid, Spain

Kiev Centre for AIDS, Kiev, Ukraine

Luhansk State Medical University, Luhansk, Ukraine

Odessa Region AIDS Center, Odessa, Ukraine

**HivBivus (Sweden):**

Central coordination: L. Morfeldt, G. Thulin, A. Sundström.

Participating physicians (city): B. Åkerlund (Huddinge); K. Koppel, A. Karlsson (Stockholm); L. Flamholc, C. Håkangård (Malmö).
The ICONA Foundation (Italy):

BOARD OF DIRECTORS

A d’Arminio Monforte (President), A Antinori, A Castagna, F Castelli, R Cauda, G Di Perri, M Galli, R Iardino, G Ippolito, GC Marchetti, CF Perno, F von Schloesser, P Viale

SCIENTIFIC SECRETARY

A d’Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti

STEERING COMMITTEE


STATISTICAL AND MONITORING TEAM

A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M Shanyinde, A Tavelli

BIOLOGICAL BANK INMI

F Carletti, S Carrara, A Di Caro, S Graziano, F Petrone, G Prota, S Quartu, S Truffa

PARTICIPATING PHYSICIANS AND CENTERS
Italy A Giacometti, A Costantini, V Barocci (Ancona); G Angarano, L Monno, C Santoro (Bari); F Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); F Castelli, C Minardi, E Quiros Roldan (Brescia); T Quirino, C Abeli (Busto Arsizio); PE Manconi, P Piano (Cagliari); B Cacopardo, B Celesia (Catania); J Vecchiet, K Falasca (Chieti); A Pan, S Lorenzotti (Cremona); L Sighinolfi, D Segala (Ferrara); F Mazzotta, F Vichi (Firenze); G Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazzarello (Genova); C Mastroianni, V Belvisi (Latina); P Bonfanti, I Caramma (Lecco); A Chiodera, P Milini (Macerata); A d’Arminio Monforte, M Galli, A Lazzarin, G Rizzardini, M Puoti, A Castagna, G Marchetti, MC Moioli, R Piolini, AL Ridolfo, S Salpietro, C Tincati, (Milano); C Mussini, C Puzzolante (Modena); A Gori, G Lapadula (Monza); N Abrescia, A Chiriani, G Borgia, R Orlando, G Bonadies, F Di Martino, I Gentile, L Maddaloni (Napoli); AM Cattelan, S Marinello (Padova); A Cascio, C Colomba (Palermo); F Baldelli, E Schiaroli (Perugia); G Parruti, F Sozio (Pescara); G Magnani, MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R Cauda, A Cristaudo, V Vullo, R Acinapura, G Baldin, M Capozzi, S Cicalini, A Cingolani, L Fontanelli Sulekova, G Iaiani, A Latini, I Mastorosara, MM Plazzi, S Savinelli, A Vergori (Roma); M Cecchetto, F Viviani (Rovigo); G Madeddu, P Bagella (Sassari); A De Luca, B Rossetti (Siena); A Franco, R Fontana Del Vecchio (Siracusa); D Francisci, C Di Giuli (Terni); P Caramello, G Di Perri, S Bonora, GC Orofino, M Sciandra (Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza) G Starnini, A Ialungo(Viterbo).

Nice HIV Cohort (France):


**SHCS (Swiss HIV Cohort Study, Switzerland):**

The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36 private physicians (listed in http://www.shcs.ch/180-health-care-providers).

Members of the Swiss HIV Cohort Study:

References


Table 1: Unadjusted and adjusted association between baseline sAlb value and a) any SNAE, b) any CVD event, and c) any NADM, obtained from Poisson regression analysis.

<table>
<thead>
<tr>
<th></th>
<th>Unadjusted RR (95% CI)</th>
<th>p-value</th>
<th>Adjusted aRR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a) Any SNAE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>4.57 (3.74, 5.58)</td>
<td>&lt;0.0001</td>
<td>3.57 (2.89, 4.40)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>≥30, &lt;35</td>
<td>2.52 (2.07, 3.07)</td>
<td>&lt;0.0001</td>
<td>2.30 (1.88, 2.82)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>≥35, &lt;40</td>
<td>1.50 (1.31, 1.71)</td>
<td>&lt;0.0001</td>
<td>1.33 (1.16, 1.52)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>≥40, &lt;45</td>
<td>Ref.</td>
<td>-</td>
<td>Ref.</td>
<td>-</td>
</tr>
<tr>
<td>≥45, &lt;50</td>
<td>0.77 (0.67, 0.89)</td>
<td>&lt;0.001</td>
<td>0.82 (0.71, 0.95)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>≥50</td>
<td>0.63 (0.45, 0.89)</td>
<td>&lt;0.01</td>
<td>0.73 (0.51, 1.03)</td>
<td>0.07</td>
</tr>
<tr>
<td>Albumin (continuous, per 5g/L)</td>
<td>0.75 (0.73, 0.78)</td>
<td>&lt;0.0001</td>
<td>0.79 (0.76, 0.82)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>b) Any CVD event</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>1.12 (0.55, 2.29)</td>
<td>0.75</td>
<td>1.23 (0.60, 2.51)</td>
<td>0.58</td>
</tr>
<tr>
<td>≥30, &lt;35</td>
<td>1.79 (1.16, 2.74)</td>
<td>&lt;0.01</td>
<td>2.33 (1.50, 3.62)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>≥35, &lt;40</td>
<td>1.34 (1.03, 1.75)</td>
<td>0.03</td>
<td>1.31 (1.00, 1.71)</td>
<td>0.05</td>
</tr>
<tr>
<td>≥40, &lt;45</td>
<td>Ref.</td>
<td>-</td>
<td>Ref.</td>
<td>-</td>
</tr>
<tr>
<td>≥45, &lt;50</td>
<td>0.83 (0.64, 1.07)</td>
<td>0.15</td>
<td>0.81 (0.62, 1.07)</td>
<td>0.13</td>
</tr>
<tr>
<td>≥50</td>
<td>0.60 (0.30, 1.17)</td>
<td>0.13</td>
<td>0.63 (0.32, 1.24)</td>
<td>0.18</td>
</tr>
<tr>
<td>Albumin (continuous, per 5g/L)</td>
<td>0.87 (0.80, 0.94)</td>
<td>&lt;0.001</td>
<td>0.87 (0.80, 0.94)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>c) Any NADM event</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>2.44 (1.63, 3.66)</td>
<td>&lt;0.0001</td>
<td>1.98 (1.28, 3.04)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>≥30, &lt;35</td>
<td>1.64 (1.14, 2.36)</td>
<td>&lt;0.01</td>
<td>1.54 (1.05, 2.24)</td>
<td>0.03</td>
</tr>
<tr>
<td>≥35, &lt;40</td>
<td>1.12 (0.89, 1.41)</td>
<td>0.32</td>
<td>1.00 (0.79, 1.26)</td>
<td>0.98</td>
</tr>
<tr>
<td>≥40, &lt;45</td>
<td>Ref.</td>
<td>-</td>
<td>Ref.</td>
<td>-</td>
</tr>
<tr>
<td>Albumin (continuous, per 5g/L)</td>
<td>0.84 (0.79, 0.89)</td>
<td>&lt;0.001</td>
<td>0.88 (0.82, 0.95)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Adjusted for participating cohort, gender, risk group, race, and the following covariates defined at baseline: age, BMI, smoking status, dyslipidaemia, total cholesterol, ALT, eGFR, HCV, HBV, CD4, VL≤50 copies/ml, current exposure to NRTIs, PIs, NNRTIs and INSTIs. Abbreviations: CVD, cardiovascular disease; NADM, non-AIDS defining malignancy; RR, rate ratio; SNAE, serious non-AIDS event.
Figure 1. Interactions of serum albumin with age group, follow up time, smoking status, CD4 count and viral load levels.

<table>
<thead>
<tr>
<th>Stratified by age group</th>
<th>aRR [95%CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;30 years, Albumin (per 5 g/L)</td>
<td>0.73 [0.54, 0.99]</td>
</tr>
<tr>
<td>&gt;30, &lt;50 years, Albumin (per 5 g/L)</td>
<td>0.77 [0.73, 0.81]</td>
</tr>
<tr>
<td>&gt;50 years, Albumin (per 5 g/L)</td>
<td>0.82 [0.77, 0.87]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stratified by follow up time</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1-24 months, Albumin (per 5 g/L)</td>
<td>0.75 [0.72, 0.73]</td>
</tr>
<tr>
<td>25-48 months, Albumin (per 5 g/L)</td>
<td>0.88 [0.82, 0.95]</td>
</tr>
<tr>
<td>49-72 months, Albumin (per 5 g/L)</td>
<td>0.83 [0.73, 0.94]</td>
</tr>
<tr>
<td>&gt;72 months, Albumin (per 5 g/L)</td>
<td>0.82 [0.74, 0.91]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stratified by smoking status</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Current smoker, Albumin (per 5 g/L)</td>
<td>0.76 [0.72, 0.83]</td>
</tr>
<tr>
<td>Ex-smoker, Albumin (per 5 g/L)</td>
<td>0.78 [0.73, 0.83]</td>
</tr>
<tr>
<td>Never smoker, Albumin (per 5 g/L)</td>
<td>0.87 [0.80, 0.93]</td>
</tr>
<tr>
<td>Not known, Albumin (per 5 g/L)</td>
<td>0.98 [0.76, 1.27]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stratified by CD4 count</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;200, Albumin (per 5 g/L)</td>
<td>0.73 [0.67, 0.83]</td>
</tr>
<tr>
<td>200-350, Albumin (per 5 g/L)</td>
<td>0.79 [0.73, 0.85]</td>
</tr>
<tr>
<td>350-500, Albumin (per 5 g/L)</td>
<td>0.83 [0.76, 0.91]</td>
</tr>
<tr>
<td>&gt;500, Albumin (per 5 g/L)</td>
<td>0.81 [0.76, 0.85]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stratified by viral load</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Suppressed, Albumin (per 5 g/L)</td>
<td>0.82 [0.78, 0.86]</td>
</tr>
<tr>
<td>Non-suppressed, Albumin (per 5 g/L)</td>
<td>0.73 [0.69, 0.77]</td>
</tr>
</tbody>
</table>

P-value for interactions was <0.0001 for age, <0.001 for CD4 count, and 0.79 for follow-up time. The association for current smokers was different than for never-smokers (p-value<0.01, see results) and different for virally suppressed individuals vs. non-suppressed (p-value<0.001). Abbreviations: aRR, adjusted rate ratio.